Legato Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Legato Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.58M	Buy	87,297 +16,492	+23%	+$856K	0.46%	35
2026 Q1	$3.41M	Buy	70,805 +7,668	+12%	+$340K	0.31%	91
2025 Q4	$2.6M	Buy	63,137 +5,496	+10%	+$220K	0.22%	113
2025 Q3	$2.24M	Buy	57,641 +7,000	+14%	+$227K	0.24%	118
2025 Q2	$1.4M	Sell	50,641 -122	-0.2%	-$3.11K	0.17%	190
2025 Q1	$1.13M	Sell	50,763 -616	-1%	-$12.7K	0.15%	220
2024 Q4	$1.02M	Sell	51,379 -15,726	-23%	-$359K	0.13%	293
2024 Q3	$1.68M	Buy	67,105 +187	+0.3%	+$4.55K	0.21%	153
2024 Q2	$1.25M	Hold	66,918	–	–	0.17%	203
2024 Q1	$1.32M	Hold	66,918	–	–	0.16%	213
2023 Q4	$1.17M	Hold	66,918	–	–	0.15%	224
2023 Q3	$1.16M	Sell	66,918 -3,143	-4%	-$53K	0.17%	203
2023 Q2	$986K	Buy	70,061 +22,751	+48%	+$305K	0.13%	265
2023 Q1	$509K	Buy	+47,310	New	+$623K	0.09%	354

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Legato Capital Management's KNSA Position: Q2 2026 in Review

Legato Capital Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 23% in Q2 2026, buying an estimated $856K and bringing the position to 87,297 shares worth $5.58M. The position accounts for 0.46% of the portfolio, ranked #35.

Legato Capital Management first reported a position in KNSA in Q1 2023 and has held it in 14 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Legato Capital Management held 87,297 shares of Kiniksa Pharmaceuticals worth $5.58M as of Q2 2026.
Legato Capital Management bought 16,492 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $856K.
Kiniksa Pharmaceuticals made up 0.46% of Legato Capital Management's portfolio in Q2 2026, its #35 holding.
Legato Capital Management first reported a position in Kiniksa Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.